Prevalence and characteristics of DM in TB patients vary considerably between countries, underlining the need for country and setting specific information. However, in all four countries, the majority of DM among TB patients was previously diagnosed but poorly controlled. Amongst individuals with TB-DM DM complications were highly prevalent as were comorbidities and CVD risk was raised. 
Introduction
Prevalence of type 2 Diabetes Mellitus (DM) has been increasing in low and middleincome countries (LMICs), in areas that also have high TB incidence [1, 2] . DM increases the risk of active TB 3-fold and worsens disease outcomes [3] . There were about 10 million cases of TB and 1.3 million deaths due to TB globally in 2017 [4] . Global TB incidence rates are currently modestly declining, and rising DM prevalence threatens global TB control [4] .Despite expanding evidence on the effect of DM on TB risk and outcome, and increasing insights upon mechanisms underlying these effects [5] , there are limited global data on those with combined TB and DM. Neither the Global Tuberculosis Report (2018) [4] or related World Health Organization (WHO) documents report TB-DM numbers worldwide (in contrast to the national level data on TB-HIV), which makes assessment of the burden of this co-morbidity challenging. Much of the available TB-DM data is based on retrospective studies, which could underestimate the scale of TB-DM comorbidity, particularly as a high proportion of DM is believed to be undiagnosed in LMICs [6] . Furthermore, most studies have been conducted on cohorts of TB patients using routine or administrative data (e.g. TB program registries) in which key risk factor and clinical data associated with DM (such as hypertension, anthropometric measures, cardiovascular health, DM duration, medication or control) are not routinely recorded.
This data gap constrains capacity to provide a complete characterization of patients with TB-DM and hinders the ability to design appropriate TB-DM screening and management strategies.
As part of an EU-funded consortium [7] , TB patients from four epidemiologically distinct settings (Indonesia, Peru, Romania and South Africa) were investigated for co-morbid 7 DM, facilitating standardized, prospective comparison of populations with differences in DM and TB prevalence, ethnicity and health systems. We report the country specific, age-adjusted prevalence and clinical characteristics of TB patients presenting with previously diagnosed DM, newly diagnosed DM, and intermediate hyperglycaemia, along with an evaluation of possible risk factors, amongst newly diagnosed TB patients in each setting.
Material and methods

Study design and study population
This study was part of TANDEM [7] , a consortium exploring the interaction between TB and DM. Details of the sites and definitions were described elsewhere [8] .
Study measurements and definitions
We defined individuals with pulmonary TB if they initiated treatment at a local TB program, based on bacteriological (sputum smear, sputum culture or Xpert test), radiological and/or clinical evidence. Further details are published elsewhere [9, 10] and are freely available in online appendices [8] .
All participants underwent laboratory HbA1c testing (using the High Performance Liquid Chromatography method), as recommended by WHO for DM screening,[11] regardless of their previous DM status. Random plasma glucose (RPG) was measured and if >110 mg/dL but <200 mg/dL (the recognised cut point for diagnosing DM if symptomatic) this was also followed with a fasting blood glucose (FPG) test. Patients were deemed to have DM if they had repeated tests (HbA1c, RPG or FPG) above the diagnostic threshold, see Appendix 1. [18] . To assess TB severity, we used TB score, which is a simple clinical score used for clinical monitoring of TB, and haemoptysis [19] .
Data analysis
We used REDCap 6.9.1 [20] TB patients with newly and previously diagnosed DM were of similar age (52.1 vs 51.0; Table 1 ).
Discussion
In this multi-country cohort patients with newly diagnosed TB had a high prevalence of both newly diagnosed (3.8%) and previously known ( Patients with previously diagnosed DM often had serious comorbidities and DM complications such as chronic kidney disease which itself is an independent risk factor for TB [35] , and microvascular and/or macrovascular complications. Patients with newly diagnosed DM had fewer DM complications, but more severe TB, despite better glycaemic control, suggesting that some of those newly diagnosed were experiencing "transient hyperglycaemia" due to severe TB. In general, TB patients with diabetes appeared to have somewhat worse TB disease compared to those without DM.
For patients with TB-DM an important consideration in the aftermath of successful TB treatment is glycemic control and management of cardiovascular risk associated with DM. Despite poor glycemic control, only 20% of TB patients with previously known DM used insulin, and only 61% used metformin. Also, hypertension was common but often untreated. These figures are in line with significant gaps in management of DM in general that we found in these same settings [36] .
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The between-country heterogeneity for certain parameters (HbA1c and BMI distributions) highlights the inherent variability across different populations and epidemiological settings. Though this observation is a finding that stresses the importance of understanding the local in-country epidemiology, it adds complexity to analyses which pool data from such diverse sites. We used robust standard errors to adjust for clustering within sites, and included country as a random effect in our regression modelling.
A potential limitation of this study is that laboratory tests were taken at the time of This study has many strengths: all patients were screened for DM with HbA1c, a standardized and validated measure in accredited laboratories, and the recruitment processes were standardized (using case record forms, standard operating procedures, and standardized definitions of all major variables), which enhances the cross-site comparability. In contrast to many studies of DM prevalence among TB patients, a repeated laboratory based measure was used for screening. 
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